Ordering Recommendation

Useful for general screening in contexts of compliance and/or abuse. For follow-up testing of a presumptive result, confirmatory testing by mass spectrometry is recommended. For automatic reflex testing on all presumptive positives, Drug Panel 9A, Urine - Screen with Reflex to Confirmation/Quantitation (0092187) is recommended.

Mnemonic
CDTI9A
Methodology

Qualitative Enzyme Multiplied Immunoassay Technique/Alcohol Dehydrogenase

Performed

Sun-Sat

Reported

1-2 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Random urine.

Specimen Preparation

Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Specimens exposed to repeated freeze/thaw cycles.

Remarks
Stability

Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years

Reference Interval

Effective August 17, 2015

Drugs Covered and Cutoff Concentrations
Drugs
Screen
THC (Cannabinoids) 20 ng/mL
Cocaine 150 ng/mL
Opiates 300 ng/mL
Oxycodone 100 ng/mL
Phencyclidine 25 ng/mL
Amphetamines 300 ng/mL
MDMA (Ecstasy) 500 ng/mL
Barbiturates 200 ng/mL
Benzodiazepines 200 ng/mL
Methadone 150 ng/mL
Propoxyphene 300 ng/mL
Alcohol 40 mg/dL

Interpretive Data

This is a screening test only. False positive and false negative results can occur. Positive results are not automatically reflexed to a confirmatory test Confirmation by GC/MS and/or LC-MS/MS must be requested separately. Confirmatory testing for drugs and/or drug classes detected by this screening test is recommended.

The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

The following opioids are not detected in this test, but can be ordered separately: fentanyl, buprenorphine, meperidine, tramadol, and tapentadol. A comprehensive panel that includes these opioids is available or individual opioid testing can be ordered. Refer to aruplab.com for test information.

For medical purposes only; not valid for forensic use.

No compliance statements are in use for this test.

Note

To order testing for individual opioids, refer to Fentanyl and Metabolite - Confirmation/Quantitation - Urine (ARUP test code 0092570), Buprenorphine and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2010092), Meperidine and Metabolite Quantitative, Urine (ARUP test code 3000248), Tramadol and Metabolites - Confirmation/Quantitation - Urine (ARUP test code 2002736). For the comprehensive panel, refer to Pain Management Drug Panel by High-Resolution Time-of-Flight Mass Spectrometry and Enzyme Immunoassay, Urine (ARUP test code 2007479).

Hotline History
N/A
CPT Codes

80307

Components
Component Test Code* Component Chart Name LOINC
0090381 Amphetamines, Urn, Screen 3349-8
0090382 Barbiturates, Urn, Screen 3377-9
0090383 Benzodiazepines, Urn, Screen 3390-2
0090386 Creatinine, Urine 2161-8
0090387 Propoxyphene, Urn, Screen 19141-1
0090388 Cocaine, Urn, Screen 3397-7
0090389 Methadone, Urn, Screen 3773-9
0090396 Opiates, Urn, Screen 3879-4
0090397 Phencyclidine, Urn, Screen 19659-2
0090398 THC, Urn, Screen 18282-4
0090419 Drug Panel 9A, Screen Only - Comments
0090488 Alcohol, Urn, Screen 5644-0
2004776 Oxycodone, Urn, Screen 19644-4
2004778 MDMA, Urn, Screen 19571-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Dolophine
  • Pain Management
Drugs of Abuse 9A Panel, Urine - Screen Only